vannesb
Registered
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
+ Author Affiliations
- Alexandra Keller,
- Zida Wu1,
- Juergen Kratzsch2,
- Eberhard Keller,
- Werner F Blum3,
- Astrid Kniess4,
- Rainer Preiss5,
- Jens Teichert5,
- Christian J Strasburger1 and
- Martin Bidlingmaier6
- Hospital for Children and Adolescents, University of Leipzig, Oststr. 21–25, D-04317 Leipzig, Germany, [SUP]1[/SUP]Division of Clinical Endocrinology, Department of Medicine, Charité University-Medicine, 10117 Berlin, Germany, [SUP]2[/SUP]Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, 61350 Leipzig, Germany, [SUP]3[/SUP]Eli Lilly & Co., Bad Homburg, Germany and Children’s Hospital, University of Giessen, 01731 Giessen, Germany, [SUP]4[/SUP]Institute of Doping Analysis and Sports Biochemistry, 04107 Kreischa, Germany, [SUP]5[/SUP]Institute of Clinical Pharmacology, University of Leipzig, Leipzig, Germany and [SUP]6[/SUP]Department of Internal Medicine, Ludwig Maximillian University of Munich, 80336 Munich, Germany
- (Correspondence should be addressed to A Keller; Email: alexandra.keller@medizin.uni-leipzig.de)
Abstract
Objective: Pharmacokinetic and pharmacodynamic data after recombinant human GH (rhGH) administration in adults are scarce, but necessary to optimize replacement therapy and to detect doping. We examined pharmacokinetics, pharmacodynamics, and 20 kDa GH after injection of rhGH at different doses and routes of administration.
Design: Open-label crossover study with single boluses of rhGH.
Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection.
Results: Serum GH maximal concentration (C[SUB]max[/SUB]) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (C[SUB]max[/SUB] 35.5 and 12.0 μ g/l; AUC 196.2 and 123.8). C[SUB]max[/SUB] and AUC were higher in males than in females (P < 0.01) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study.
Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.
Great information bro!